Serum coenzyme Q10 levels are associated with coronary flow reserve in hemodialysis patients

Hemodialysis International

Volumn 17, Issue 3, 2013, Pages 339-345

  Macunluoglu, Beyza ^a   Kaya, Yuksel ^e   Atakan, Aydin ^b   Ari, Elif ^e   Kaspar, Cigdem ^d   Demir, Halit ^f   Alp, Hamit Hakan ^g   Asicioglu, Ebru ^c   Kedrah, Alla Eldeen ^c  

^a Uskudar State Hospital   (Turkey)

^b Fatih Sultan Mehmet Hospital   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d YEDITEPE UNIVERSITY   (Turkey)

^e Van Yuksek Ihtisas Hospital   (Turkey)

^f YUZUNCU YIL UNIVERSITY   (Turkey)

^g ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Coenzyme Q10; Coronary flow reserve; Hemodialysis

Indexed keywords

UBIDECARENONE;

ADULT; ARTICLE; BLOOD LEVEL; COENZYME Q10 BLOOD LEVEL; CONTROLLED STUDY; CORONARY FLOW RESERVE; CORRELATIONAL STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; CORONARY CIRCULATION; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; UBIQUINONE;

EID: 84879600658     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12001     Document Type: Article

References (32)

1. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis. 1992; 19:505-513.
2. Dursun B, Dursun E, Suleymanlar G, etal. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant. 2008; 23:1697-1703.
3. Koch M, Gradaus F, Schoebel FC, etal. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant. 1997; 12:1187-1191.
4. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005; 68:1413-1418.
5. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. Suppl. 2003; 63:105-110.
6. Anderson TJ. Assessment and treatment of endothelial dysfunction. J Am Coll Cardiol. 1999; 34:631-638.
7. Rigo F. Coronary flow reserve in stress-echo lab. From pathophysiologic toy to diagnostic tool. Cardiovasc Ultrasound. 2005; 3:8.
8. Gould KL, Lipscomb K. Effects of coronary stenoses on coronary flow reserve and resistance. Am J Cardiol. 1974; 34:48-55.
9. Vita JA, Keaney JF Jr, Raby KE, etal. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol. 1998; 31:980-986.
10. Nyyssönen K, Porkkala-Sarataho E, Kaikkonen J, etal. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis. 1997; 130:223-233.
11. Hozumi T, Yoshida K, Ogata Y, etal. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation. 1998; 97:1557-1562.
12. Caliskan Y, Oflaz H, Demirturk M, etal. Coronary flow reserve dysfunction in hemodialysis and kidney transplant patients. Clin Transplant. 2008; 22:785-793.
13. Caliskan Y, Demirturk M, Ozkok A, etal. Coronary artery calcification and coronary flow velocity in hemodialysis patients. Nephrol Dial Transplant. 2010; 25:2685-2690.
14. Galderisi M, Cicala S, Caso P, etal. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol. 2002; 90:860-864.
15. Gorgulu N, Yelken B, Caliskan Y, etal. Endothelial dysfunction in hemodialysis patients with failed renal transplants. Clin Transplant. 2010; 24:678-684.
16. Finckh B, Kontush A, Commentz J, etal. High-performance liquid chromatography-coulometric electrochemical detection of ubiquinol 10, ubiquinone 10, carotenoids, and tocopherols in neonatal plasma. Methods Enzymol. 1999; 299:341-348.
17. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician. 2005; 72:1065-1070.
18. Lin YS, Hung SC, Wei YH, etal. GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. J Am Soc Nephrol. 2009; 20:405-415.
19. Tarng DC, Huang TP, Wei YH, etal. 8-Hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis. 2000; 36:934-944.
20. Gokbel H, Atalay H, Okudan N, etal. Coenzyme Q10 and its relation with oxidant and antioxidant system markers in patients with end-stage renal disease. Ren Fail. 2011; 33:677-681.
21. Triolo L, Lippa S, Oradei A, etal. Serum coenzyme Q10 in uremic patients on chronic hemodialysis. Nephron. 1994; 66:153-156.
22. Ishii T, Ohtake T, Okamoto K, etal. Serum biological antioxidant potential predicts the prognosis of hemodialysis patients. Nephron Clin Pract. 2011; 117:230-236.
23. Niklowitz P, Sonnenschein A, Janetzky B, etal. Enrichment of coenzyme Q10 in plasma and blood cells: Defense against oxidative damage. Int J Biol Sci. 2007; 3:257-262.
24. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001; 94:1112-1117.
25. Rosenfeldt FL, Haas SJ, Krum H, etal. Coenzyme Q10 in the treatment of hypertension: A meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21:297-306.
26. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009; (4): CD007435.
27. Gao L, Mao Q, Cao J, etal. Effects of coenzyme Q10 on vascular endothelial function in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2011; 221:311-316.
28. Sakata T, Furuya R, Shimazu T, etal. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008; 26:371-378.
29. Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left ventricular hypertrophy. Blood Press. 2010; 19:40-47.
30. Calişkan M, Ciftçi O, Güllü H, Müderrisoǧlu H. The effect of carvedilol therapy on coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Turk Kardiyol Dern Ars. 2008; 36:247-252.
31. Galderisi M, D'Errico A. Beta-blockers and coronary flow reserve: The importance of a vasodilatory action. Drugs. 2008; 68:579-590.
32. Toyama T, Sato C, Koyama K, etal. Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. Cardiology. 2012; 122:230-236.